Ilinpru Combi

Metformin Hydrochloride and Linagliptin, the active ingredient in Ilinpru Combi, is a Biguanide/DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Ilinpru Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilinpru Combi is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels. It helps achieve glycaemic control when used alone or in combination with other antidiabetic agents.

- Type 2 diabetes mellitus: improves fasting plasma glucose and HbA1c levels. - Inadequate control on metformin alone: provides additional glucose‑lowering effect. - Combination therapy: allows simplified dosing with two complementary mechanisms.

Ilinpru Combi may cause a range of adverse reactions, most of which are mild and reversible. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Dizziness: transient episodes, especially on standing. - Upper respiratory tract symptoms: mild cough or sore throat.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycaemia: especially when combined with sulfonylureas or insulin. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Ilinpru Combi, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function assessment: confirm adequate eGFR and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hepatic disease: use with caution and monitor liver enzymes. - Pregnancy and lactation: discuss potential risks and benefits with the prescriber. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Ilinpru Combi can interact with several medicines, requiring careful management to avoid adverse outcomes.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 ml/min/1.73 m²): contraindicated due to lactic acidosis risk. - Potent CYP3A4 inhibitors: may increase linagliptin exposure. - Duplicate DPP‑4 inhibition: avoid using with other DPP‑4 inhibitors. - High‑dose metformin plus sulfonylureas: heightened hypoglycaemia risk. - Iodinated contrast agents: may precipitate renal dysfunction.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolytes. - ACE inhibitors or ARBs: watch for changes in renal function and potassium levels. - Alcohol consumption: may increase risk of lactic acidosis.